Clinical Trial

A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.
Protocol Amendment History 3 changes
notable Sponsor changed: Stanford University -> Clarion Cells, Inc. 2026-08-13
notable Enrollment reduced: 30 -> 27 participants 2026-08-12
notable Sponsor changed: Gary Steinberg, MD, PhD -> Stanford University 2026-08-12
Trial Details
NCT Number NCT04631406
Lead Sponsor Clarion Cells, Inc.
Conditions Ischemic Stroke
Enrollment 27 participants
Start Date 2021-01-04
Primary Completion 2025-08-12 (estimated)
Study Completion 2029-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12